Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Doctor OctoPlus

This article was originally published in The Gray Sheet

Executive Summary

SurModics obtains an option to acquire an exclusive license from OctoPlus for the OctoDEX and PolyActive biodegradable drug delivery polymers. SurModics plans to use the technology, which is suitable for use with proteins and large molecule therapeutic agents, as biodegradable coatings or as fully degradable products. PolyActive is used for controlled release of proteins and hydrophobic small molecule drugs. OctoDEX is based on "cross-linked dextran microspheres" used for timed release of proteins and large particles, such as liposomes and antigens. Both polymers are undergoing preclinical and clinical evaluation for use as pharmaceutical formulations...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT020503

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel